We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Amazon.com, Novartis, Philip Morris International, Automatic Data Processing and Live Nation Entertainment
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 19, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Novartis AG (NVS - Free Report) , Philip Morris International Inc. (PM - Free Report) , Automatic Data Processing, Inc. (ADP - Free Report) and Live Nation Entertainment, Inc. (LYV - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Amazon, Novartis and Philip Morris
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Novartis AG and Philip Morris International Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Amazon.com shares have been big laggards this year, on account primarily of two distinct factors.
First, Amazon's growth outlook has gotten cloudier as a result of the uncertain macroeconomic backdrop resulting from the Fed's extraordinary tightening policy that has raised recessionary risks for the U.S. economy. Second, Amazon's near-term growth outlook is weighed down by the pulled-forward growth during Covid. The company heavily invested in human and physical capacity during Covid that has produced somewhat of a mismatch between 'capacity' and demand growth that they are currently in the process of rationalizing through lay-offs and facility shutdowns.
The stock is down -47.9% this year vs. the -17.2% decline for the S&P 500 index and the Zacks Retail sector's -26.5% pullback. Amazon's main Retail sector rival Walmart is up +4.8% this year.
Nevertheless, Amazon's third quarter results were driven by Prime and AWS momentum. Strengthening AWS services portfolio and its growing adoption rate contributed well.
Ultrafast delivery services and expanding content portfolio were beneficial. Strengthening relationship with third-party sellers was a positive. Robust advertising business contributed well. Improving Alexa skills along with robust smart home products offerings were tailwinds.
Amazon's strong global presence and solid momentum among the small and medium businesses remain positives. Growing capabilities in grocery, pharmacy, Amazon Care, Kuiper and Zoox are other positives. Considering the abovementioned facts, the Zacks analyst expects 2022 revenue to be up 8.3% from 2021.
Novartis' shares have gained +5.9% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +15.1%. The company's performance in the third quarter was pretty ho-hum, as earnings beat by a penny but revenues lagged due to generic competition.
With the planned spin off of Sandoz, Novartis is looking to become a pure-play pharmaceutical company. Novartis has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug Cosentyx, cardiovascular drug Entresto, gene therapy Zolgensma, the oncology portfolio and the launch of Kesimpta continue to boost performance.
The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent and the label expansion of key drugs should also boost performance further. Management's focus on cost savings should boost the bottom line as well. However, generic competition for key drugs and pipeline setbacks are concerns.
Philip Morris' shares have outperformed the Zacks Tobacco industry over the past year (+8.4% vs. +3.7%). The company has been benefiting from its strong pricing power. Also, focus on reduced risk products, especially IQOS has been working well for the company, which is witnessing continued product mix shift from cigarettes to smoke-free products. However, Philip Morris has been battling cost-related headwinds. In third-quarter 2022, the proforma adjusted operating income margin fell 1 point on an organic basis.
Management lowered its proforma adjusted operating margin organic growth view for 2022, wherein it expects gross margin contraction due to a considerable rise in IQOS device volumes, the increased initial cost of IQOS ILUMA, elevated logistic costs, growth-oriented investments in the smoke-free space, raw material and energy cost inflation and incremental supply-chain costs.
Other noteworthy reports we are featuring today include Automatic Data Processing, Inc. and Live Nation Entertainment, Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Amazon.com, Novartis, Philip Morris International, Automatic Data Processing and Live Nation Entertainment
For Immediate Release
Chicago, IL – December 19, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Novartis AG (NVS - Free Report) , Philip Morris International Inc. (PM - Free Report) , Automatic Data Processing, Inc. (ADP - Free Report) and Live Nation Entertainment, Inc. (LYV - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Amazon, Novartis and Philip Morris
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Novartis AG and Philip Morris International Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Amazon.com shares have been big laggards this year, on account primarily of two distinct factors.
First, Amazon's growth outlook has gotten cloudier as a result of the uncertain macroeconomic backdrop resulting from the Fed's extraordinary tightening policy that has raised recessionary risks for the U.S. economy. Second, Amazon's near-term growth outlook is weighed down by the pulled-forward growth during Covid. The company heavily invested in human and physical capacity during Covid that has produced somewhat of a mismatch between 'capacity' and demand growth that they are currently in the process of rationalizing through lay-offs and facility shutdowns.
The stock is down -47.9% this year vs. the -17.2% decline for the S&P 500 index and the Zacks Retail sector's -26.5% pullback. Amazon's main Retail sector rival Walmart is up +4.8% this year.
Nevertheless, Amazon's third quarter results were driven by Prime and AWS momentum. Strengthening AWS services portfolio and its growing adoption rate contributed well.
Ultrafast delivery services and expanding content portfolio were beneficial. Strengthening relationship with third-party sellers was a positive. Robust advertising business contributed well. Improving Alexa skills along with robust smart home products offerings were tailwinds.
Amazon's strong global presence and solid momentum among the small and medium businesses remain positives. Growing capabilities in grocery, pharmacy, Amazon Care, Kuiper and Zoox are other positives. Considering the abovementioned facts, the Zacks analyst expects 2022 revenue to be up 8.3% from 2021.
(You can read the full research report on Amazon.com here >>>)
Novartis' shares have gained +5.9% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +15.1%. The company's performance in the third quarter was pretty ho-hum, as earnings beat by a penny but revenues lagged due to generic competition.
With the planned spin off of Sandoz, Novartis is looking to become a pure-play pharmaceutical company. Novartis has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug Cosentyx, cardiovascular drug Entresto, gene therapy Zolgensma, the oncology portfolio and the launch of Kesimpta continue to boost performance.
The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent and the label expansion of key drugs should also boost performance further. Management's focus on cost savings should boost the bottom line as well. However, generic competition for key drugs and pipeline setbacks are concerns.
(You can read the full research report on Novartis here >>>)
Philip Morris' shares have outperformed the Zacks Tobacco industry over the past year (+8.4% vs. +3.7%). The company has been benefiting from its strong pricing power. Also, focus on reduced risk products, especially IQOS has been working well for the company, which is witnessing continued product mix shift from cigarettes to smoke-free products. However, Philip Morris has been battling cost-related headwinds. In third-quarter 2022, the proforma adjusted operating income margin fell 1 point on an organic basis.
Management lowered its proforma adjusted operating margin organic growth view for 2022, wherein it expects gross margin contraction due to a considerable rise in IQOS device volumes, the increased initial cost of IQOS ILUMA, elevated logistic costs, growth-oriented investments in the smoke-free space, raw material and energy cost inflation and incremental supply-chain costs.
(You can read the full research report on Philip Morris here >>>)
Other noteworthy reports we are featuring today include Automatic Data Processing, Inc. and Live Nation Entertainment, Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.